igor krylov  pharmstandard international sa  zoominfocom pharmstandard international sa  zoominfocom insider trading  pharmstandard international sa  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  pharmstandard international sa select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view purchase  pm argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view purchase  pm argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view purchase  pm argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view purchase  am argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view purchase  am argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view purchase  pm argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view purchase  pm argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view purchase  pm argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view purchase  pm argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view purchase  pm argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view purchase  pm argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner    indirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing purchase  pm  argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner   indirect view purchase  pm  argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner   indirect view purchase  pm  argos therapeutics inc args pharmstandard international sapublic joint stock co pharmstandard owner   indirect view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  pharmstandard international sa private company information  bloomberg july    am et capital markets company overview of pharmstandard international sa snapshot people company overview pharmstandard international sa specializes in making investments in innovative drugstherapies with strong potential in global markets and in russia  testovskaya streetmoscow  russiafounded in  phone      fax      key executives for pharmstandard international sa pharmstandard international sa does not have any key executives recorded pharmstandard international sa key developments pharmstandard signs loan agreement with pharmstandard international sa mar   on march   pharmstandard pao signed a loan agreement with pharmstandard international sa parties to the deal pharmstandard  lender pharmstandard international sa  borrower the deal is valued at usd  million which accounts for  of the issuers assets value the date to perform the obligations under the agreement is march   similar private companies by industry company name region metropol investment financial company ltd europe alemar investment group europe absolut invest europe advance capital europe alor invest ltd europe recent private companies transactions typedate target private placement june   argos therapeutics inc private placement march   engene inc private placement march   avelas biosciences inc request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact pharmstandard international sa please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close pharmstandard international sa ceo and executives  bloomberg july    am et capital markets company overview of pharmstandard international sa snapshotpeople  overviewboard memberscommittees key executives for pharmstandard international sa nameboard relationshipstitleagethere is no key executives data available pharmstandard international sa board members nameboard relationshipsprimary companyagethere is no board members data available pharmstandard international sa executive committees committee namechairpersonboard relationshipsmembersthere is no committee data available data is at least as current as the most recent definitive proxy request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup ceo compensation in this industry  industry range industry executive changesthere is no executive change data availablesponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact pharmstandard international sa please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close argos therapeutics inc nasdaqargs files an k entry into a material definitive agreement  market exclusive sign in join home about us privacy policy disclaimer advertise on market exclusive about marketexclusivecom contributors sitemap submit a scoop contact us become a contributor stock market news stocks analyst ratings insider trading sec filings earnings biotech stocks small caps sign in welcomelog into your accountyour usernameyour password forgot your password sign up welcomeregister for an account your emailyour username a password will be emailed to you password recovery recover your passwordyour email search sign in  joinmy account orders sign inwelcome log into your accountyour usernameyour password forgot your password get helpcreate an account create an accountwelcome register for an accountyour emailyour username a password will be emailed to you password recoveryrecover your passwordyour email a password will be emailed to you market exclusive home about us privacy policy disclaimer advertise on market exclusive about marketexclusivecom contributors sitemap submit a scoop contact us become a contributor stock market news stocks analyst ratings insider trading sec filings earnings biotech stocks small caps home sec filings argos therapeutics inc nasdaqargs files an k entry into a material definitive sec filings argos therapeutics inc nasdaqargs files an k entry into a material definitive agreement byme staff k june    share on facebook tweet on twitter argos therapeutics inc nasdaqargs files an k entry into a material definitive agreementitem  entry into a material definitive agreement   on june   argos therapeutics inc the “company” entered into a note purchase agreement the “note purchase agreement” with pharmstandard international sa “pharmstandard” to which the company agreed to issue and sell to pharmstandard a convertible secured promissory note in the original principal amount of  the “note” in a private placement the “financing” the company will issue the note to pharmstandard on the closing date of the financing under the note the maturity date for the payment of principal and interest will be the fifth anniversary of the issue date the note will bear interest at a rate of  per annum which interest will compound annually the note will be secured by a lien on and security interest in all of the company’s intellectual property the company may prepay the note in whole or in part at any time without penalty or premium upon the occurrence of certain events of default pharmstandard will have the option to require the company to repay the unpaid principal amount of the note and any unpaid accrued interest in addition at pharmstandard’s election pharmstandard may convert the entire principal and interest on the note into shares of the company’s common stock at a price per share equal to  which is the product of  and the closing price of the company’s common stock on the nasdaq global market on june   however pharmstandard will not be permitted to convert the entire note if such conversion would result in pharmstandard and its affiliates holding shares that exceed  of the total number of outstanding shares of common stock of the company or  of the combined voting power of all outstanding securities of the company to the extent that conversion of the entire note would cause pharmstandard and its affiliates to exceed these thresholds pharmstandard may convert a portion of the note to the extent these thresholds are not exceeded by such partial conversion pharmstandard is the company’s largest stockholder and beneficially owned in the aggregate shares representing approximately  of the company’s outstanding common stock as of april   in addition two members of the company’s board of directors are closely associated with pharmstandard the company has agreed to pay the legal expenses of pharmstandard including legal expenses incurred in connection with the resale registration obligations of the company set forth in the registration rights agreement provided however that the company shall have no obligation to pay more than a total of  with respect to such expenses the company has granted pharmstandard and pharmstandard has granted the company indemnification rights with respect to their respective representations warranties covenants and agreements under the note purchase agreement the closing is expected to occur on june   and is subject to the satisfaction of certain customary closing conditions security agreement   in connection with the issuance of the note the company will enter into a security agreement with pharmstandard on the date of the closing of the financing  to the security agreement the company will grant to pharmstandard a firstpriority lien on and security interest in substantially all of its intellectual property collateral and will agree with certain exceptions not to incur certain future indebtedness and liens or to sell transfer license or otherwise dispose of any material portion of the intellectual property collateral upon the occurrence of events of default under the note pharmstandard will have certain rights to the intellectual property collateral as set forth in the security agreement registration rights agreement   on june   in connection with entering into the note purchase agreement the company entered into a registration rights agreement the “registration rights agreement” with pharmstandard to which the company has agreed to register for resale the shares of the company’s common stock issued or issuable upon conversion of the note the “conversion shares” under the registration rights agreement the company has agreed to use its best efforts to file a registration statement covering the conversion shares within  days of the closing and to use its best efforts to keep such registration statement effective until the date the conversion shares have been sold or may be sold to rule  without restriction in the event that a registration statement has not been filed by the company within  days of the closing subject to extension under certain circumstances the company has agreed to pay to pharmstandard as liquidated damages an amount equal to  of the product of the number of registrable securities and the conversion price of the conversion shares the “conversion amount” for each day period or pro rata for any portion thereof during which no such registration statement is filed moreover in the event i the registration statement is not declared effective by the securities and exchange commission the “sec” by the th day following the closing or ii after the registration statement has been declared effective by the sec the registration statement is not available to cover any sales of conversion shares then the company has agreed to pay pharmstandard as liquidated damages an amount equal to  of the conversion amount held by pharmstandard for each day period or pro rata for any portion thereof following the date by which the registration statement should have been effective subject to specified exceptions  the company has granted pharmstandard and pharmstandard has granted to the company customary indemnification rights in connection with the registration statement the foregoing descriptions of the note purchase agreement and the registration rights agreement are qualified in their entirety by reference to the full text of the note purchase agreement and the registration rights agreement copies of which are filed as exhibits  and  hereto respectively and incorporated by reference herein the foregoing descriptions of the note and the security agreement are qualified in their entirety by reference to the full text of the note and the security agreement forms of which are included as exhibits to the note purchase agreement in exhibit  and incorporated by reference herein item  unregistered sales of equity securities   the information contained above in item  is hereby incorporated by reference into this item  based in part upon the representations of pharmstandard in the note purchase agreement the note will be issued and sold in reliance upon the exemption from the registration requirements of the securities act of  as amended the “securities act” set forth in section a of the securities act the issuance of the note has not been registered under the securities act or any state securities laws and may not be offered or sold in the united states absent registration with the sec or an applicable exemption from the registration requirements the sale of the note will not involve a public offering pharmstandard represented that it is an accredited investor as such term is defined in rule a of regulation d under the securities act and that it is acquiring the note for investment purposes only and not with a view to any resale distribution or other disposition of the note in violation of the united states federal securities laws and the company took reasonable steps to verify that pharmstandard is an accredited investor as such term is defined in rule a of regulation d under the securities act item  other events   on june   the company issued a press release announcing the sale of the note the full text of the press release issued in connection with this announcement is attached as exhibit  to this form k and incorporated herein by reference as of march   the company had cash and cash equivalents of  million and working capital of  million the company expects that its cash and cash equivalents together with the proceeds from the closing of the financing only will enable it to continue its business operations through august  however even with the proceeds from the sale of the note the company will not have sufficient cash resources to pay its obligations as they become due or to fund the company’s operations until the point at which the company has reached  events in its phase  adapt trial of rocapuldencelt and has the associated data the company has initiated discussions with saintgobain performance plastics corporation invetech pty ltd and medpace inc regarding the fees that the company owes them but there can be no assurance that the company will be able to enter into any arrangement with any of these parties on favorable terms on a timely basis or at all therefore the company will need to raise additional capital in order to continue to operate its business the company expects to seek to raise additional capital through the sale of equity or convertible debt alternatively the company may seek to engage in one or more potential transactions such as the sale of the company a strategic partnership with one or more parties or the licensing sale or divestiture of some of its assets or proprietary technologies but there can be no assurance that the company will be able to enter into such a transaction or transactions on a timely basis or on terms that are favorable to the company or at all under these circumstances the company may instead determine to dissolve and liquidate its assets or seek protection under the bankruptcy laws if the company decides to dissolve and liquidate its assets or to seek protection under the bankruptcy laws it is unclear to what extent the company will be able to pay its obligations and accordingly it is further unclear whether and to what extent any resources will be available for distributions to stockholders the  annual meeting of stockholders the “ annual meeting” of the company has been scheduled for july   because the date of the  annual meeting is more than  days after the anniversary date of the  annual meeting of stockholders the “ annual meeting” in accordance with rule af under the securities exchange act of  as amended the “exchange act” the company is informing stockholders of such date proposals of stockholders intended to be presented at the  annual meeting must be received by us no later than june   in order to be included in our proxy statement and form of proxy relating to that meeting these proposals must comply with the requirements as to form and substance established by the securities and exchange commission for such proposals in order to be included in our proxy statement for the  annual meeting in addition our bylaws establish an advance notice procedure for nominations for election to our board of directors and other matters that stockholders wish to present for action at an annual meeting other than those to be included in our proxy statement the deadline for stockholder proposals submitted to the advance notice procedure in our bylaws has passed  important additional information any statements in this form k about the company’s future expectations plans and prospects including statements about the expected and potential future closing of the financing the company’s financial prospects anticipated use of proceeds future operations and sufficiency of funds for future operations and future expectations and plans and prospects for the company and other statements containing the words “believes” “anticipates” “estimates” “expects” “intends” “plans” “predicts” “projects” “targets” “may” “potential” “will” “would” “could” “should” “continue” and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including whether the conditions for the closing of the financing will be satisfied whether the company’s cash resources will be sufficient to fund its continuing operations for the periods anticipated whether the company will be able to raise additional financing on a timely basis whether the company will be able to enter into arrangements with creditors the impact of the analysis of the data and discussions with the us food and drug administration on the development of rocapuldencelt the impact of the recommendation of the independent data monitoring committee on the continuation of the adapt trial whether results obtained in clinical trials will be indicative of results obtained in future clinical trials whether the company’s product candidates will advance through the clinical trial process on a timely basis whether the results of such trials will warrant submission for approval from the fda or equivalent foreign regulatory agencies whether the company’s product candidates will receive approval from regulatory agencies on a timely basis or at all whether if product candidates obtain approval they will be successfully distributed and marketed whether argos can successfully establish commercial manufacturing operations on a timely basis or at all and other factors discussed in the “risk factors” section of the company’s most recent quarterly report on form q filed with the sec and in other filings the company makes with the sec from time to time in addition the forwardlooking statements included in this form k represent the company’s views as of the date hereof the company anticipates that subsequent events and developments will cause the company’s views to change however while the company may elect to update these forwardlooking statements at some point in the future the company specifically disclaims any obligation to do so these forwardlooking statements should not be relied upon as representing the company’s views as of any date subsequent to the date hereof item  financial statements and exhibits   the exhibits to this current report on form k are listed in the exhibit index attached hereto         about argos therapeutics inc nasdaqargs argos therapeutics inc argos is an immunooncology company the company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called arcelis the company’s arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies the company is engaged in the development of ags for the treatment of metastatic renal cell carcinoma mrcc and other cancers it is conducting a pivotal phase iii clinical trial of ags plus sunitinib or another targeted therapy for the treatment of newly diagnosed mrcc under a special protocol assessment spa it is engaged in the development of ags for the treatment of human immunodeficiency virus hiv it has conducted over three clinical trials of ags including a phase iib clinical trial phase iia clinical trial and phase i clinical trial please enable javascript to view the comments powered by disqusan ad to help with our costs related articlesmore from author canadian pacific railway limited tsecp files an k other events duos technologies group inc otcmktsduot files an k entry into a material definitive agreement vectren corporation nysevvc files an k entry into a material definitive agreement technovative group inc otcmktstehg files an k departure of directors or certain officers election of directors appointment of certain officers compensatory arrangements of certain pacific continental corporation nasdaqpcbk files an k financial statements and exhibits mendocino brewing company inc otcmktsmenb files an k entry into a material definitive agreement subscribe to our newsletter email  first namelast nameemail a word from the sponsor latest articles pingtan marine enterprise ltd nasdaqpme files an k results of operations and financial condition rayonier advanced materials inc nyseryam files an k financial statements and exhibits armstrong world industries inc nyseawi files an k submission of matters to a vote of security holders recent posts canadian pacific railway limited tsecp files an k other events duos technologies group inc otcmktsduot files an k entry into a material definitive agreement vectren corporation nysevvc files an k entry into a material definitive agreement technovative group inc otcmktstehg files an k departure of directors or certain officers election of directors appointment of certain officers compensatory arrangements of certain officers pacific continental corporation nasdaqpcbk files an k financial statements and exhibits sponsored editor picks biotech movers johnson  johnson nysejnj and pfizer inc nysepfe july   biotech movers tesaro inc nasdaqtsro and mylan nv nasdaqmyl july   novartis ag adr nysenvs just took a big step forward in july   popular posts this small nasdaq hidden gem may have a b drug july   weekly biotech report covering – opko health inc nyseopk intercept april   facebook inc – nasdaqfb might be moving away from its april   popular categorysec filingslsestockstech newsbiotech stocksstock market newssmall capscanadapress releases about usmarket exclusive offers the latest financial news and analysis for selected us stocks and securities we are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions at market exclusive we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices market exclusive is not a registered investment brokerdealer the content on this site is for informational purposes only additionally the content on this site does not represent the views of market exclusive and is solely a representation of the authors who publish them before investing in any security you should do your own due diligence and consult with a registered broker or financial advisorcontact us email protectedfollow us sec filings stocks stock market news tech news biotech stocks featured small caps gold other news oil become a contributor about marketexclusivecom contributors advertise on market exclusive contact us  market exclusive  pharmstandard international sa top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active pharmstandard international sa • luxembourg n how do i update this listing pharmstandard international sa is based out of luxembourg their last reported f filing for q  included  in managed f securities and a top  holdings concentration of  pharmstandard international sas largest holding is jounce therapeutics inc with shares held of  whalewisdom has at least  fs and  dg filings in our database for pharmstandard international sa summary f holdings ind managers dg insider form  download f summary to excel download f summary to excel create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from pharmstandard international sa enter your email address below and choose submit your email cancel  top buys name change jnce jounce therapeutics   top sells name change args call argos therapeuti   f holdings summary stock port jnce jounce therapeutics inc  ptgx protagonist tpts  args argos therapeuti  prto proteon theraptc  args call argos therapeuti  see all holdings  f activity market value  million prior market value  million new purchases stock additional purchases stocks sold out of stocks reduced holdings in stocks top  holdings  turnover   turnover alt   time held top quarters time held top quarters time held all quarters  turnover is calculated by taking the  of new holdings initial purchases  the  of positions sold out of not just reduced divided by the total  of holdings for the quarter  alt turnover is calculated by taking either the total mv of new purchases or the mv of securities sold whichever is less divided by the total mv of the fund  f sector allocation over time fund metrics you are limited to the prior  quarters of f filings subscribe to whalewisdom to view all filing data for pharmstandard international sa portfolio performance top  equalweighted holdings last updated on  performance for q  not ready yet performance last  quarters  performance metrics stats are not available for the latest quarter backtester use whalewisdoms backtester tool to test how a hypothetical portfolio would have performed with different investment strategies research one or more filers performance and then optimize their portfolios to match your own investment goals start with one of our predefined groups or create your own view the backtesting whitepaper and the getting started page for additional help take a tour save changes to tracked backtest saving generate report at least one fund must be selected before running a backtest  ending sector allocation quarter to view current combined fdg q  f filings q  f filings refresh advanced export download csv download excel xlsx download tsv click to see additional filters security types shares calls puts principal changes in holdings new position added to position reduced position closed out position no change ranking is in the top minimum  of shares stock ticker is etf yesno refresh edit columns shares are split adjusted × report an error your name optional your email optional error to report or any other commentsrequired cancel click here to report any possible errors with this listing f filings available   fhr subscription required   fhr subscription required × csv export module this will schedule a job to export all requested f holdings data for this filer when completed an email will be sent to the email address you specify containing a link to download the zip file of the csv files you requested output type output all f holdings into a single csv file output all f holdings into separate csv files per quarter columns to include filer name stock name stock ticker quarter date type of security current shares held current market value previous shares held previous market value current  of portfolio previous  of portfolio current rank previous rank change in shares type of change sector f quarters to include   email address to send data to cancel schedule export this lets you look at individual sub managers or subsidiaries within the f filing quarter   manager optionally compare to quarter    manager  number of shares is not splitadjusted schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free the official website pharmstandard  development and manufacture of advanced medicines about us investors business partners career newsroom contact us   pharmstandard — russias leading pharmaceutical group committed to development and manufacture of advanced highquality affordable medicines our principles innovation efficiency responsibility download annual report  manufacturing capacity bln packs per year production lines stateoftheart gmpcertified plants products over  pharmaceutical products  dosage forms over  medicines included in the vital and essential drugs list business partners stateoftheart plants with welldeveloped logistics support for your business at every manufacturing and marketing stage consumers drug safety control anticounterfeiting health professionals wide range of rx and otc drugs recent publications of research results newsroom all news  the ministry of health of the russian federation has expressed concern over more  pharmstandard has changed its legal form more  pharmstandard wins the allrussian open competition platinum ounce more  pharmstandard wins the bestru  award more anticorruption and law enforcement pharmstandard group ensures compliance with the laws and ethical business practices please report if any action of our employee appears to you as a possible violation send a message drug safety monitoring pharmstandard group deeply cares about its product safety and consumer health send a message cancel career about us group profile company structure quality standards business partners our companies areas of cooperation development quality management investors performance highlights ifrs financial statements annual reports newsroom our news media about us contact us b likhachyovsky proezd dolgoprudny moscow region  russia       – all rights reserved jsc pharmstandard terms of use disclosure of information предупреждение информация на сайте предназначена исключительно для медицинских работников подтвердите пожалуйста являетесь ли вы медицинским работником если вы не являетесь медицинским работником пожалуйста покиньте данный раздел сайта я ознакомлен с соглашением и согласен с его пожеланиями соглашение о получении информации о рецептурных препаратах на сайте представлена информация о рецептурных препаратах их свойствах способах применения и возможных противопоказаниях исключительно специалистам здравоохранения лицам имеющим высшее или среднее специальное медицинское образование  если вы являетесь специалистом здравоохранения и хотите получить информацию с данного раздела сайта вам необходимо подтвердить ваш статус специалиста здравоохранения  в случае если вы не являетесь специалистом здравоохранения но в нарушение настоящих условий подписываете данное соглашение сайт компании не несет ответственности за возможные отрицательные последствия возникшие в результате самостоятельного использования вами информации с сайта без предварительной консультации со специалистом вы делаете это самостоятельно и осознанно понимая что применение рецептурных препаратов возможно только после предварительной консультации со специалистом здравоохранения  информация о рецептурных препаратах представленная на данном разделе сайте предназначена исключительно для ознакомления с препаратами и не является руководством для самостоятельной диагностики или лечения и не служит в качестве медицинских советов или рекомендаций сайт не несет ответственности за возможный ущерб нанесенный вашему здоровью в случае самовольного лечения проводимого на основании применения рецептурных препаратов без предварительной консультации со специалистом настоящим я подтверждаю что являюсь специалистом здравоохранения и подтверждаю своё согласие с тем что применение рецептурных препаратов возможно только после предварительной консультации со специалистом нет я не являюсь медицинским работником да я являюсь медицинским работником news  inbio ventures русскийenglishaboutmanagement teaminvestment focusfund i portfolionewscontact us our portfolio company jounce therapeutics announced pricing of initial public offeringfriday january th  moscow russia jan   – a portfolio company of pharmstandard international sa jounce therapeutics inc a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers announced the pricing of its initial public offering of  shares of common stock at a public offering price of  per share for aggregate gross proceeds of  in addition jounce granted the underwriters a day option to purchase up to  additional shares of its common stock at the initial public offering price the shares are scheduled to begin trading on the nasdaq global select market on january   under the ticker symbol “jnce”jp morgan and cowen and company are acting as joint bookrunning managers for the offering wells fargo securities is acting as lead manager and baird is acting as a comanager for the offeringa registration statement relating to these securities has been filed with and was declared effective by the securities and exchange commission on january   the offering will be made only by means of a prospectus a copy of the final prospectus relating to the offering will be filed with the securities and exchange commission and may be obtained when available from jp morgan securities llc co broadridge financial solutions  long island avenue edgewood ny  or by telephone at   or cowen and company llc co broadridge financial services  long island avenue edgewood ny  attn prospectus department telephone  this press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction about jounce therapeuticsjounce therapeutics inc is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients through the use of our translational science platform we first focus on specific cell types within tumors to prioritize targets and then identify related biomarkers designed to match the right therapy to the right patient jounce was launched in  with funding from leading life sciences investor third rock ventures in july  jounce announced a global strategic collaboration with celgene corporationmedia contactdan budwickpure communications inc danpurecommunicationsinccominvestor contactbeth delgiaccostern investor relations inc bethsternircom about pharmstandard international sa  inbio venturespharmstandard international sa – is a company with the main focus on venture investments in innovative medicinestherapies with strong potential both globally and in russia pharmstandard international sa is a fully owned subsidiary of pjsc pharmstandard lsephst – russia’s leading pharmaceutical producer for more information please visit wwwpharmstdluinbio ventures jsc – is a management company representing pharmstandard international sa and providing professional support in venture transactions for more information please visit httpwwwinbioventurescom pharmstandard international represented by inbio ventures participated in series b financing of neon therapeuticsthursday january th  moscow russia – january   – pharmstandard international and inbio ventures today have announced successful completion of series b financing in neon therapeutics thus adding the th equity investment to the portfolio neon is immunooncology company developing neoantigenbased therapeutic vaccines and t cell therapies to treat cancer the proceeds will be used to advance the lead program neopv a fully personalized neoantigen vaccine through an ongoing phase b clinical trial in addition this investment will support preclinical development of neoptc a personalized adoptive t cell program and the shared neoantigen program the  million series b financing was led by partner fund management and joined by existing investors third rock ventures and access industries besides pharmstandard international additional new investors included fidelity management  research company wellington management company and nextech invest “we are pleased to join a strong syndicate of investors” commented alexey vinogradov chief executive officer of inbio ventures a management company representing pharmstandard international sa “with outstanding quality of innovation and the team neon is poised to lead the field of neoantigenbased therapeutics one of the most promising topics in cancer immunotherapy today” “the investor quality in this financing reflects the promise of the neoantigen biology platform as well as our leading position” said hugh o’dowd chief executive officer of neon therapeuticsabout neon therapeutics neon therapeutics is an immunooncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer a neoantigenbased product engine allows neon to develop multiple treatment modalities including nextgeneration vaccines and t cell therapies targeting both personalized and shared neoantigens neon’s lead program is a personalized neoantigen vaccine that builds upon years of research and development at the broad institute and danafarber cancer institute and is already in clinical trials for more information please visit wwwneontherapeuticscomabout pharmstandard international sa  inbio ventures pharmstandard international sa – is a company with the main focus on venture investments in innovative medicinestherapies with strong potential both globally and in russia pharmstandard international sa is a fully owned subsidiary of pjsc pharmstandard lsephst – russia’s leading pharmaceutical producer for more information please visit wwwpharmstdlu inbio ventures jsc – is a management company representing pharmstandard international sa and providing professional support in venture transactions for more information please visit httpwwwinbioventurescom pharmstandard international sa represented by inbio ventures leads a m syndicated series c financing in avelas biosciencesthursday august th  moscow august   – pharmstandard international sa led the the series c financing which raised  million in new funds for avelas biosciences along with pharmstandard international sa the syndicate included other new investors ervington investments limited and alexandria equities llc as well as existing investors avalon ventures bregua corporation and wuxi healthcare venturesavelas biosciences inc is a clinical stage oncologyfocused company dedicated to improving cancer patient care from diagnosis through treatment the proceeds from series c financing will be used to advance avb a “cancer illuminator” into latestage clinical trials and to develop new targeted therapeutics for cancer as well as for general corporate purposesin conjunction with the financing andrei petrov phd the chief executive officer and managing partner at inbio ventures has joined avelas bioscience’s board of directors at the same time kevin kinsella and nikolay savchuk will be stepping down as directors of the company“i am delighted to have some of the world’s most prominent healthcare investors participate in our series c financing led by pharmstandard” said carmine n stengone president and chief executive officer of avelas biosciences “strengthened by this fundraising i believe avelas is wellpositioned to further the development of avb and advance new therapeutic candidates – two exciting product opportunities that could make meaningful contributions to cancer diagnosis and treatment”avelas’ core technology takes advantage of cancer’s inherent biochemical pathology to deliver cargo either therapeutic or imaging to the cancer site the first product candidate avb is a fluorescent cancerilluminating probe that “lights up” when it interacts with cancer cells the purpose of avb is to enable cancer surgeons to distinguish between tumor and healthy tissue during surgery avb may be able to offer the necessary realtime information needed by surgeons to visualize and excise cancerous tissue while they operate avoiding the need for additional surgeriesabout avelas biosciencesavelas biosciences is a san diegobased biotechnology company focused on developing technologies that advance a new standardofcare for cancer surgery and therapeutic intervention the company’s lead product candidate avb is in a phase b trial in breast cancer to assess safety pharmacokinetics and fluorescence properties using tissue image analysis avelas was founded by avalon ventures on technology from nobel laureate roger y tsien phd for additional information please visit wwwavelasbiocom our portfolio company protagonist therapeutics has successfully completed initial public offeringthursday august th  protagonist is the fourth company in our portfolio that successfully went public on nasdaq pharmstandard international has participated in the offering the upsized ipo was completed at  per share that represents a solid stepup to previous investment roundsmoscow russia august   – a portfolio company of pharmstandard international sa protagonist therapeutics inc nasdaq ptgx that is a clinicalstage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptidebased new chemical entities to address significant unmet medical needs announced on august   the pricing of its initial public offering of  shares of common stock at a price to the public of  per share before underwriting discounts and commissions the shares began trading on the nasdaq global market on august   under the symbol “ptgx” in addition protagonist has granted the underwriters a day option to purchase up to  additional shares at the initial public offering price less underwriting discounts and commissions this offering closed on august   subject to customary closing conditions a registration statement relating to these securities has been filed with the securities and exchange commission and was declared effective on august  about pharmstandard international sa  inbio venturespharmstandard international sa – is a company with the main focus on venture investments in innovative medicinestherapies with strong potential both globally and in russia pharmstandard international sa is a fully owned subsidiary of pjsc pharmstandard lsephst – russia’s leading pharmaceutical producer for more information please visit wwwpharmstdlu inbio ventures jsc – is a management company representing pharmstandard international sa and providing professional support in venture transactions for more information please visit httpwwwinbioventurescom  copy  inbio ventures group profile  the official website pharmstandard about us investors business partners career newsroom contact us   pharmstandard russias leading pharmaceutical group committed to development and manufacture of advanced highquality affordable medicines that meet the healthcare requirements and patients’ expectations pharmaceutical products new products essential drugs mission “development and manufacture of advanced pharmaceutical products compliant with the healthcare requirements and patients’ expectations” pharmstandard group manufactures medicines of various pharmacotherapeutic groups including those for treatments of cardiovascular diseases diabetes growth hormone deficiency gastroenterological neurological contagious diseases metabolic disorders cancer and other diseases group profile company structure pharmstandard jsc phsleksredstva jsc pharmstandardufavita jsc phstomskhimpharm jsc lekko cjsc jsc “biomed” mechnikov “pharmapark” llc pharmstandard llc photo  video gallery quality standards corporate governance compliance corporate governance bodies general shareholders meeting board of directors management board disclosure of information annual financial statements company annual reports the company’s total manufacturing capacity exceeds  bln packs per year pharmstandard group’s manufacturing facilities comprise  stateoftheart pharmaceutical plants phsleksredstva jsc kursk pharmstandardufavita jsc ufa phstomskhimpharm jsc tomsk lekko cjsc volginsky settlement vladimir region jsc “biomed” mechnikov moscow moscow region “pharmapark” llc moscow gmp and iso quality standards stateoftheart plants packs per year pharmstandard llc moscow manages raw material purchase and supply to ensure subsequent manufacturing of pharmaceutical products at pharmstandard group facilities phstomskhimpharm jsc the largest manufacturer of finished pharmaceutical products in western siberia gmpcertified since  the company celebrated its th anniversary in  pharmstandardufavita jsc one of the largest pharmaceutical manufacturers in russia apart from vitamins the company manufactures a wide range of medicines of other pharmacotherapeutic groups at present its portfolio includes more than  product names phsleksredstva jsc the company ranks in the top largest pharmaceutical manufacturers in russia and actively participates in the state import substitution program manufacturing capacity over  mln packs per year pharmstandard llc pharmstandard jsc lekko cjsc“pharmapark” llc jsc ”biomed” mechnikov the russian innovative company expertizes in rd manufacturing and promotion of highly efficient medicinal products with its over  year old success story in the market russias leading pharmaceutical company ensures development and distribution of advanced medicines that meet the healthcare requirements and patients’ expectations manages purchase and supply of raw materials including auxiliaries and packaging materials to ensure subsequent manufacturing of pharmaceutical products at pharmstandard group facilities russias largest manufacturer of alphab interferon that has successfully entered foreign markets the company participates in state import substitution and social welfare programs one of the oldest manufacturers of immunobiological products core activities manufacturing of vaccines interferons probiotics immune modulators and other pharmaceutical products manufacturing of diagnostic products and microbiological media contract manufacturing footprint more all the group manufacturing facilities fully comply with the russian standards phsleksredstva jsc and pharmstandardufavita jsc production sites are eu gmpcertified all the group manufacturing facilities fully comply with the russian standards phsleksredstva jsc and pharmstandardufavita jsc production sites have obtained the certificates of compliance with the international standards at phsleksredstva jsc  production lines are eu gmpcertified by the group management adoption there is a program in place to convert all the plants to the european gmp standards principles strategy social responsibility in its operations the group is committed to the following fundamental principles innovation — immediate implementation of cuttingedge developments in medicine and pharmacology in close cooperation with russian and international scientists efficiency — business process management based on an efficient and balanced combination of scientifictechnical innovations and extensive expertise gained by the group over the years of sound activities in the pharmaceutical market responsibility — application of international management and process standards as part of the group responsibility to the customer compliance with environmental standards and reduction of industrial impact on the environment in the context of responsibility to future generations strategic development areas of the group development and introduction of new products extension of the formulation range and dosage forms in order to meet market demand and customers expectations to the maximum enhancement of manufacturing localization through joint projects with leading foreign pharmaceutical companies extension of groups product portfolio with highmargin pharmaceuticals increase of groups participation in the state import substitution program automation of production planning processes in order to increase efficiency of process management and strengthen cost control within the frames of its strategic development the group invests heavily in development and upgrade of its manufacturing facilities pharmstandard group the undisputed leader in russian pharma manufacturing guarantees the highest quality standards of the manufactured pharmaceuticals to its customers the underlying principles of pharmstandard social policy have been brought into line with russias national policy of medicine procurement stipulating substitution of expensive imported pharmaceuticals with affordable local products manufactured in compliance with the highest international standards pharmstandard is known for its commitment to product safety and efficacy to take up these challenges the group has implemented a rigorous internal system of pharmacovigilance aimed at collection and analysis of information on adverse events and drug interactions as well as effective coordination with the relevant regulatory authorities being highly socially responsible pharmstandard provides focused support to vulnerable social groups and social welfare institutions on a regular basis the group highly appreciates doctors and patients’ trust in the pharmaceuticals manufactured under pharmstandard trademark and continuously invests in development of new products and refinement of manufacturing technologies career about us group profile company structure quality standards business partners our companies areas of cooperation development quality management investors performance highlights ifrs financial statements annual reports newsroom our news media about us contact us b likhachyovsky proezd dolgoprudny moscow region  russia       – all rights reserved jsc pharmstandard terms of use disclosure of information предупреждение информация на сайте предназначена исключительно для медицинских работников подтвердите пожалуйста являетесь ли вы медицинским работником если вы не являетесь медицинским работником пожалуйста покиньте данный раздел сайта я ознакомлен с соглашением и согласен с его пожеланиями соглашение о получении информации о рецептурных препаратах на сайте представлена информация о рецептурных препаратах их свойствах способах применения и возможных противопоказаниях исключительно специалистам здравоохранения лицам имеющим высшее или среднее специальное медицинское образование  если вы являетесь специалистом здравоохранения и хотите получить информацию с данного раздела сайта вам необходимо подтвердить ваш статус специалиста здравоохранения  в случае если вы не являетесь специалистом здравоохранения но в нарушение настоящих условий подписываете данное соглашение сайт компании не несет ответственности за возможные отрицательные последствия возникшие в результате самостоятельного использования вами информации с сайта без предварительной консультации со специалистом вы делаете это самостоятельно и осознанно понимая что применение рецептурных препаратов возможно только после предварительной консультации со специалистом здравоохранения  информация о рецептурных препаратах представленная на данном разделе сайте предназначена исключительно для ознакомления с препаратами и не является руководством для самостоятельной диагностики или лечения и не служит в качестве медицинских советов или рекомендаций сайт не несет ответственности за возможный ущерб нанесенный вашему здоровью в случае самовольного лечения проводимого на основании применения рецептурных препаратов без предварительной консультации со специалистом настоящим я подтверждаю что являюсь специалистом здравоохранения и подтверждаю своё согласие с тем что применение рецептурных препаратов возможно только после предварительной консультации со специалистом нет я не являюсь медицинским работником да я являюсь медицинским работником